Targets for molecular therapy of skin cancer

Seminars in Cancer Biology

Volumn 14, Issue 1, 2004, Pages 63-69

  Green, Cheryl L ^b   Khavari, Paul A ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal cell carcinoma; Cancer; Melanoma; Skin; Squamous cell carcinoma

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ARF PROTEIN; CYCLIN DEPENDENT KINASE 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P14; PROTEIN P16; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SONIC HEDGEHOG PROTEIN;

BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER CELL DESTRUCTION; CANCER INCIDENCE; GENE MUTATION; GENE TRANSFER; GENETIC DISORDER; HUMAN; MELANOMA; NONHUMAN; ONCOGENE RAS; PROTEIN BINDING; PROTEIN DEGRADATION; REVIEW; SKIN TUMOR; SQUAMOUS CELL CARCINOMA;

EID: 0742304317     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.11.007     Document Type: Article

References (76)

1. Owens D.M., Watt F.M. Contribution of stem cells and differentiated cells to epidermal tumours. Nat. Rev. Cancer. 3:2003;444-451.
2. Miller D.L., Weinstock M.A. Nonmelanoma skin cancer in the United States: incidence. J. Am. Acad. Dermatol. 30:1994;774-778.
3. Miller S.J. Biology of basal cell carcinoma (Part I). J. Am. Acad. Dermatol. 24:1991;1-13.
4. Miller S.J. Biology of basal cell carcinoma (Part II). J. Am. Acad. Dermatol. 24:1991;161-175.
5. Carucci JA, Lefell DJ. Basal cell carcinoma, in Freedberg IM, et al., editors. Dermatology in General Medicine. McGraw-Hill Press, New York, 2003: 747-54.
6. Cherpelis B.S., Marcusen C., Lang P.G. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol. Surg. 28:2002;268-273.
7. Czarnecki D., Staples M., Mar A., Giles G., Meehan C. Metastases from squamous cell carcinoma of the skin in southern Australia. Dermatology. 189:1994;52-54.
8. Grossman D, Lefell DJ. Squamous cell carcinoma, in Freedberg IM, et al., editors. Dermatology in General Medicine. McGraw-Hill Press, New York, 2003: 737-47.
9. Langley RGB, Barnhill RL, Mihm MC, Fitzpatrick TB, Sober AJ. Cutaneous melanoma, in Freedberg IM, et al., editors. Dermatology in General Medicine. McGraw-Hill Press, New York, 2003: 917-47.
10. Kanzler M.H., Swetter S.M. Malignant melanoma. J. Am. Acad. Dermatol. 48:2003;780-783.
11. Swetter S.M. Dermatological perspectives of malignant melanoma. Surg. Clin. North. Am. 83:2003;77-95.
12. Hahn H., Wicking C., Zaphiropoulous P.G., Gailani M.R., Shanley S., Chidambaram A.et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 85:1996;841-851.
13. Johnson R.L., Rothman A.L., Xie J., Goodrich L.V., Bare J.W., Bonifas J.M.et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 272:1996;1668-1671.
14. Xie J., Murone M., Luoh S.M., Ryan A., Gu Q., Zhang C.et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature. 391:1998;90-92.
15. Oro A.E., Higgins K.M., Hu Z., Bonifas J.M., Epstein E.H., Scott M.P. Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 276:1997;817-821.
16. Fan H., Khavari P.A. Sonic hedgehog opposes epithelial cell cycle arrest. J. Cell. Biol. 147:1999;71-76.
17. Nilsson M., Unden A.B., Krause D., Malmqwist U., Raza K., Zaphiropoulos P.G.et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc. Natl. Acad. Sci. U S A. 97:2000;3438-3443.
18. Grachtchouk M., Mo R., Yu S., Zhang X., Sasaki H., Hui C.C.et al. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat. Genet. 24:2000;216-217.
19. Fan H., Oro A.E., Scott M.P., Khavari P.A. Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat. Med. 3:1997;788-792.
20. Sasaki S., Kitagawa Y., Sekido Y., Minna J.D., Kuwano H., Yokota J.et al. Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene. 22:2003;3792-3798.
21. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V.et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
22. Sharpless E., Chin L. The lNK4a/ARF locus and melanoma. Oncogene. 22:2003;3092-3098.
23. Gibbs P., Brady B.M., Robinson W.A. The genes and genetics of malignant melanoma. J. Cutan. Med. Surg. 6:2002;229-235.
24. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of Gi-phase progression. Genes Dev. 13:1999;1501-1512.
25. Zuo L., Weger J., Yang Q., Goldstein A.M., Tucker M.A., Walker G.J.et al. Germlme mutations in the p1 6INK4a binding domain of CDK4 in familial melanoma. Nat. Genet. 12:1996;97-99.
26. Lazarov M., Kubo Y., Cai T., Dajee M., Tarutani M., Lin Q.et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat. Med. 8:2002;1105-1114.
27. Sherr C.J. The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell. Biol. 2:2001;731-737.
28. Kuo M.L., Duncavage E.J., Mathew R., den Besten W., Pei D., Naeve D.et al. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res. 63:2003;1046-1053.
29. Hussussian C.J., Struewing J.P., Goldstein A.M., Higgins P.A., Ally D.S., Sheahan M.D.et al. Germlme p16 mutations in familial melanoma. Nat. Genet. 8:1994;15-21.
30. Gruis N.A., van der Velden P.A., Sandkuijil L.A., Prins D.E., Weaver-Feldhaus J., Kamb A.et al. Homozygotes for CDKN2 (p16) germlme mutation in Dutch familial melanoma kindreds. Nat. Genet. 10:1995;351-353.
31. Randerson-Moor J.A., Harland M., Williams S., Cuthbert-Heavens D., Sheridan E., Aveyard J.et al. A germlme deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum. Mol. Genet. 10:2001;55-62.
32. Rizos H., Puig S., Badenas C., Malvehy J., Darmanian A.P., Jimenez L.et al. A melanoma-associated germlme mutation in exon 1 beta inactivates p14ARF. Oncogene. 20:2001;5543-5547.
33. Chin L., Pomerantz J., Polsky D., Jacobson M., Cohen C., Cordon-Carde C.et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 11:1997;2822-2834.
34. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N.et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
35. Bardeesy N., Wong K.K., DePinho R.A., Chin L. Animal models of melanoma: recent advances and future prospects. Adv. Cancer Res. 79:2000;123-156.
36. Kannan K., Sharpless N.E., Xu J., O'Hagan R.C., Bosenberg M., Chin L. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc. Natl. Acad. Sci. U S A. 100:2003;1221-1225.
37. Frame S., Balmain A. Integration of positive and negative growth signals during ras pathway activation in vivo. Curr. Opin. Genet. Dev. 10:2000;106-113.
38. Shields J.M., Pruitt K., McFall A., Shaub A., Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell. Biol. 10:2000;147-154.
39. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature. 410:2001;37-40.
40. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S.et al. Mutations of the BRAF gene in human cancer. Nature. 417:2002;949-954.
41. Albino A.P., Nanus D.M., Mentle I.R., Cordon-Cardo C., McNutt N.S., Bressler J.et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene. 4:1989;1363-1374.
42. Demunter A., Stas M., Degreef H., De WoIf-Peeters C., van den Oord J.J. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol. 117:2001;1483-1489.
43. Dajee M., Cai M.T., Khavari P.A. Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation. Oncogene. 21:2002;1527-1538.
44. Cal T., Nishida K., Hirano T., Khavari P.A. Gabi and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation. J. Cell. Biol. 159:2002;103-112.
45. Tarutani M., Cal T., Dajee M., Khavari P.A. Inducible activation of ras and raf in adult epidermis. Cancer Res. 63:2003;319-323.
46. Xie J., Aszterbaum M., Zhang X., Bonifas J.M., Zachary C., Epstein E.et al. A role of PDGFRaIpha in basal cell carcinoma proliferation. Proc. Natl. Acad. Sci. U S A. 98:2001;9255-9259.
47. Pierceall W.E., Goldberg L.H., Tainsky M.A., Mukhopadhyay T., Ananthaswamy H.N. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol. Carcinog. 4:1991;196-202.
48. Dajee M., Lazarov M., Zhang J.Y., Cai T., Green C.L., Russell A.J.et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 421:2003;639-643.
49. von Lintig F.C., Dreilinger A.D., Varki N.M., Wallace A.M., Casteel D.E., Boss G.R. Ras activation in human breast cancer. Breast Cancer Res. Treat. 62:2000;51-62.
50. Ziegler A., Jonason A.S., Leffell D.J., Simon J.A., Sharma H.W., Kimmelman J.et al. Sunburn and p53 in the onset of skin cancer. Nature. 372:1994;773-776.
51. Leffell D.J. The scientific basis of skin cancer. J. Am. Acad. Dermatol. 42:2000;18-22.
52. Campbell C., Quinn A.G., Ro Y.S., Angus B., Rees J.L. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J. Invest. Dermatol. 100:1993;746-748.
53. Greenhalgh D.A., Wang X.J., Donehower L.A., Roop D.R. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res. 56:1996;4413-4423.
54. Jiang W., Ananthaswamy H.N., Muller H.K., Kripke M.L. p53 protects against skin cancer induction by UV-B radiation. Oncogene. 18:1999;4247-4253.
55. Jia S., Flores-Saaib R.D., Courey A.J. The Dorsal Rel homology domain plays an active role in transcriptional regulation. Mol. Cell. Biol. 22:2002;5089-5099.
56. Lin L., DeMartino G.N., Greene W.C. Cotranslational dimerization of the Rel homology domain of NF-kappaBl generates p50-pi OS heterodimers and is required for effective p50 production. Embo. J. 19:2000;4712-4722.
57. Ghosh S., Karin M. 2002. Missing pieces in the NF-kappaB puzzle. Cell. 109(Suppl):2002;881-896.
58. Dixit V., Mak T.W. NF-kappaB signaling. Many roads lead to madrid. Cell. 111:2002;615-619.
59. van Hogerlinden M., Rozell B.L., Ahrlund-Richter L., Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited ReVnuclear factor-kappaB signaling. Cancer Res. 59:1999;3299-3303.
60. Seitz C.S., Lin Q., Deng H., Khavari P.A. Alterations in NF-κB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-κB. Proc. Natl. Acad. Sci. U S A. 95:1998;2307-2312.
61. Khavari P.A., Rollman O., Vahlquist A. Cutaneous gene transfer for skin and systemic diseases. J. Intern. Med. 252:2002;1-10.
62. Frank-Kamenetsky M., Zhang X.M., Bottega S., Guicherit O., Wichterle H., Dudek H.et al. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J. Biol. 1:2002;10.
63. Cox A.D., Der C.J. Ras family signaling: therapeutic targeting. Cancer Biol. Ther. 1:2002;599-606.
64. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 3:2003;11-22.
65. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nature Rev Cancer. 2:2002;301-310.
66. Orlowski R.Z., Baldwin A.S. Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 8:2002;385-389.
67. Engler T.A., Furness K., Malhotra S., Sanchez-Martinez C., Shih C., Xie W.et al. Novel, potent and selective cyclin D1ICDK4 inhibitors: [indolo[6,7-a]pyrrolo(3,4 c]carbazoles. Bioorg. Med. Chem. Lett. 13:2003;2261-2267.
68. Honma T., Hayashi K., Aoyama T., Hashimoto N., Machida T., Fukasawa K.et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. 44:2001;4615-4627.
69. Fry D.W., Bedford D.C., Harvey P.H., Fritsch A., Keller P.R., Wu Z.et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J. Biol. Chem. 276:2001;16617-16623.
70. Wang W., Takimoto R., Rastinejad F., EI-Deiry W.S. Stabilization of p53 by CP-31 398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol. 23:2003;2171-2181.
71. Waddick K.G., Uckun F.M. Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. Biochem. Pharmacol. 57:1999;9-17.
72. Prochiantz A. Messenger proteins: homeoproteins, TAT and others. Curr. Opin. Cell. Biol. 12:2000;400-406.
73. Ford K.G., Souberbielle B.E., Darling D., Farzaneh F. Protein transduction: an alternative to genetic intervention? Gene Ther. 8:2001;1-4.
74. Wadia J.S., Dowdy S.F. Protein transduction technology. Curr. Opin. Biotechnol. 13:2002;52-56.
75. Rothbard J.B., Garlington S., Lin Q., Kirschberg T., Kreider E., McGrane P.L.et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6:2000;1253-1257.
76. Robbins P.B. Peptide delivery to tissues via reversibly linked protein transduction sequences. Biotechniques. 33:2002;190-194.